Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial-Reference-Cited by-同舟云学术

Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial

Published:2018-09-27 Issue:5 Volume:58 Page:639-645
ISSN:0148-639X
Container-title:Muscle & Nerve
language:en
Short-container-title:Muscle & Nerve

Author:

Shieh Perry B.¹,Mcintosh Joseph²,Jin Fengbin²,Souza Marcio²,Elfring Gary²,Narayanan Siva²,Trifillis Panayiota²,Peltz Stuart W.²,Mcdonald Craig M.³,Darras Basil T.⁴,

Affiliation:

1. University of California, 300 UCLA Medical Plaza B‐200 Los Angeles Los Angeles, California USA

2. PTC Therapeutics, Inc. 100 Corporate Court, South Plainfield, NJ, South Plainfield New Jersey USA

3. University of California Davis School of Medicine Department of Physical Medicine and Rehabilitation, 4860 Y Street, Suite 3850 Sacramento California USA

4. Boston Children's Hospital, 300 Longwood Avenue Boston Massachusetts USA

Publisher

Wiley

Subject

Physiology (medical),Cellular and Molecular Neuroscience,Neurology (clinical),Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mus.26191

Reference28 articles.

1. Online Mendelian Inheritance in Man OMIM®.Duchenne Muscular Dystrophy. MIM Number: 310200.2017. Available at:https://omim.org/. Accessed June 19 2018.

2. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management

3. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management

4. 2014 University of Washington WA BT Darras B Korf DK Urion RA Pagon MP Adam HH Ardinger Dystrophinopathies

5. Dystrophinopathies

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models;Human Molecular Genetics;2023-10-11

2. Consensus concept of modern effective therapy for Duchenne muscular dystrophy;Neuromuscular Diseases;2023-06-15

3. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status;Journal of Comparative Effectiveness Research;2023-02-07

4. Update of the Brazilian consensus recommendations on Duchenne muscular dystrophy;Arquivos de Neuro-Psiquiatria;2023-01

5. Cardiac therapies for Duchenne muscular dystrophy;Therapeutic Advances in Neurological Disorders;2023-01